Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank. (June 2022)
- Record Type:
- Journal Article
- Title:
- Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank. (June 2022)
- Main Title:
- Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank
- Authors:
- Ho, Frederick K
Ferguson, Lyn D
Celis-Morales, Carlos A
Gray, Stuart R
Forrest, Ewan
Alazawi, William
Gill, Jason MR
Katikireddi, Srinivasa Vittal
Cleland, John GF
Welsh, Paul
Pell, Jill P
Sattar, Naveed - Abstract:
- Summary: Background: Gamma-glutamyltransferase (GGT) levels in the blood can be a sensitive marker of liver injury but the extent to which they give insight into risk across multiple outcomes in a clinically useful way remains uncertain. Methods: Using data from 293, 667 UK Biobank participants, the relationship of GGT concentrations to self-reported alcohol intake and adiposity markers were investigated. We next investigated whether GGT predicted liver-related, cardiovascular (CV) or all-cause mortality, and potentially improved CV risk prediction. Findings: Higher alcohol intake and greater waist circumference (WC) were associated with higher GGT; the association was stronger for alcohol with evidence of a synergistic effect of WC. Higher GGT concentrations were associated with multiple outcomes. Compared to a GGT of 14.5 U/L (lowest decile), values of 48 U/L for women and 60 U/L for men (common upper limits of 'normal') had hazard ratios (HRs) for liver-related mortality of 1.83 (95% CI 1.60–2.11) and 3.25 (95% CI 2.38–4.42) respectively, for CV mortality of 1.21 (95% CI 1.14–1.28) and 1.43 (95% CI 1.27–1.60) and for all-cause mortality of 1.15 (95% CI 1.12–1.18) and 1.31 (95% CI 1.24–1.38). Adding GGT to a risk algorithm for CV mortality reclassified an additional 1.24% (95% CI 0.14–2.34) of participants across a binary 5% 10-year risk threshold. Interpretation: Our study suggests that a modest elevation in GGT levels should trigger a discussion with the individual toSummary: Background: Gamma-glutamyltransferase (GGT) levels in the blood can be a sensitive marker of liver injury but the extent to which they give insight into risk across multiple outcomes in a clinically useful way remains uncertain. Methods: Using data from 293, 667 UK Biobank participants, the relationship of GGT concentrations to self-reported alcohol intake and adiposity markers were investigated. We next investigated whether GGT predicted liver-related, cardiovascular (CV) or all-cause mortality, and potentially improved CV risk prediction. Findings: Higher alcohol intake and greater waist circumference (WC) were associated with higher GGT; the association was stronger for alcohol with evidence of a synergistic effect of WC. Higher GGT concentrations were associated with multiple outcomes. Compared to a GGT of 14.5 U/L (lowest decile), values of 48 U/L for women and 60 U/L for men (common upper limits of 'normal') had hazard ratios (HRs) for liver-related mortality of 1.83 (95% CI 1.60–2.11) and 3.25 (95% CI 2.38–4.42) respectively, for CV mortality of 1.21 (95% CI 1.14–1.28) and 1.43 (95% CI 1.27–1.60) and for all-cause mortality of 1.15 (95% CI 1.12–1.18) and 1.31 (95% CI 1.24–1.38). Adding GGT to a risk algorithm for CV mortality reclassified an additional 1.24% (95% CI 0.14–2.34) of participants across a binary 5% 10-year risk threshold. Interpretation: Our study suggests that a modest elevation in GGT levels should trigger a discussion with the individual to review diet and lifestyle including alcohol intake and consideration of formal liver disease and CV risk assessment if not previously done. Funding: British Heart Foundation Centre of Research Excellence Grant (grant number RE/18/6/34217), NHS Research Scotland (grant number SCAF/15/02), the Medical Research Council (grant number MC_UU_00022/2); and the Scottish Government Chief Scientist Office (grant number SPHSU17). … (more)
- Is Part Of:
- EClinicalMedicine. Volume 48(2022)
- Journal:
- EClinicalMedicine
- Issue:
- Volume 48(2022)
- Issue Display:
- Volume 48, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 48
- Issue:
- 2022
- Issue Sort Value:
- 2022-0048-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-06
- Subjects:
- Gamma-glutamyltransferase -- Cohort studies -- Liver disease -- Alcohol -- Cardiovascular disease
BMI body mass index -- CV cardiovascular disease -- HCC hepatocellular carcinoma -- HR hazard ratio -- IHD ischaemic heart disease -- NRI net reclassification improvement -- OR odds ratio -- SCORE Systematic COronary Risk Evaluation -- WC waist circumference
Medicine -- Research -- Periodicals
Medical policy -- Periodicals
Clinical Medicine
Health Policy
Public Health
Medical policy
Medicine -- Research
Periodical
Electronic journals
Periodicals
613 - Journal URLs:
- https://www.sciencedirect.com/science/journal/25895370 ↗
http://www.sciencedirect.com/ ↗ - DOI:
- 10.1016/j.eclinm.2022.101435 ↗
- Languages:
- English
- ISSNs:
- 2589-5370
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22116.xml